Introducing the Pharma Fast 50

PharmaTimes presents Alantra’s annual look at the fastest-growing pharma companies
Resistance is futile

An exciting, futuristic chapter for clinical trials has opened in which participant engagementwill flourish, expansive data will navigate the maze of disease and digital technology will take pharma and patients to previously unexplored dimensions. John Pinching reports.
What does the next decade hold for the NHS?

Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore some of the key aspirations of the NHS’ Long Term Plan

News

View all

Long-term data shows promise in breast cancer biosimilar

The a three-year follow-up study comparing Ontruzant to Herceptin has found the biosimilar to be just as successful.

22nd March 2019

£23 million funding for cutting edge health projects

£23 million of government funding has been awarded to cutting edge health projects.

22nd March 2019

Researchers to test heart drug for COPD patients

University of Aberdeen researchers are set to test beta-blockers for COPD patients.

22nd March 2019

NICE nod for Takeda’s Adcetris in advanced stage CTCL

Takeda has announced the NICE recommendation of Adcetris for advanced cutaneous T-cell lymphoma.

22nd March 2019

Celgene and Exscientia ink three year AI drug discovery collaboration

Exscientia has announced a three-year drug discovery AI collaboration with Celgene.

22nd March 2019

Web Exclusives

View all

Unlocking the UK’s virtual drug discovery capability

The UK is well positioned to take advantage of virtual drug discovery services, says Medicines Discovery Catapult's Graeme Wilkinson

The Amazon effect

The pharma industry needs to transform the supply chain from a source of regulatory risk to a legitimate business opportunity.

Preparing your workforce for Brexit

Trouble on the horizon for pharma? A look at post-Brexit immigration.

Thumbnail image for The rise of virtual pharma

The rise of virtual business models in biopharma reflects the changing face of the pharmaceutical industry - big pharma discovering and developing its own pipeline exclusively in-house no longer exists.

Magazine

View more from the latest edition

SmartPeople: Richard Davies

Richard Davies, vice president and solutions expert at CluePoints, says there’s “a huge opportunity” for operational efficiency gains in clinical trials

SmartPeople: Lotte Bjerre Knudsen

PharmaTimes talks to Lotte Bjerre Knudsen, inventor of diabetesdrug liraglutide and scientific vice president at Novo Nordisk

A need to know basis

Ten months since sweeping data privacy laws came into force in Europe, pharma companies are wrestling with the new ‘right to be forgotten’

The rise of the CRO

Dr Chris Doherty discusses the rise of clinical research organisations (CROs) from his vantage point as managing director at Alderley Park

Resistance is futile

An exciting, futuristic chapter for clinical trials has opened in which participant engagementwill flourish, expansive data will navigate the maze of disease and digital technology will take pharma and patients to previously unexplored dimensions. John Pinching reports.

Closing the gap

How seven innovations are accelerating research and bringing new data-driven insights to the clinical trial landscape, potentially reducing the time and cost of drug development